Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre raises 2025 guidance as Q2 sales rise 15% to $64.2 million

Positive Impact 4 of 5 guidance Written later

LeMaitre Vascular reported preliminary second-quarter 2025 results, with net sales of $64.2 million, up 15%, and diluted earnings per share of $0.60, up 16%. The company raised its full-year 2025 sales and earnings guidance, now projecting sales of $248 million to $254 million and diluted EPS of $2.23 to $2.37. The results are preliminary and unaudited.

Key points

  • Q2 2025 gross margin was 70.0%, up from 68.9% a year earlier, and operating income was $16.1 million, up 12%.
  • Full-year 2025 guidance: sales of $248 million to $254 million and EPS of $2.23 to $2.37.
  • Q3 2025 guidance: sales of $61.2 million to $63.2 million and EPS of $0.54 to $0.59.
  • Board approved a $0.20 per share quarterly dividend, payable September 4, 2025, to holders of record on August 21, 2025.

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECAug 5, 2025, 4:22 PM ET
Accession number0001437749-25-024862

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.